Clinical Trial Update: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the pharmacokinetic and pharmacodynamic properties of FIAsp when administered as a bolus within a continuous subcutaneous insulin infus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Fiasp (insulin aspart)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Phase 1 | Status: COMPLETED